Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Twist Bioscience to Report Fiscal 2023 Third Quarter Financial Results on Friday, August 4, 2023


Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 third quarter ended June 30, 2023, before the opening of the market on Friday, August 4, 2023. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investor Relations section under the "Company" tab at www.twistbioscience.com.

The conference call will be webcast live through the Investor Relations section under the "Company" tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company's Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube


These press releases may also interest you

at 06:22
Smart Payment Association (SPA), the trade body of the cards and mobile payments industry, today released findings from its annual review of the smart payment...

at 06:09
On July 2, the 26th annual meeting of China Association for Science and Technology (CAST) was launched in Nanning city, Guangxi Zhuang Autonomous Region. This event is jointly hosted by the CAST and the People's Government of Guangxi Zhuang...

at 06:00
Bybit, the world's second-largest crypto exchange by trading volume, is excited to announce its partnership with BLIK, the innovative payment system in Poland, to revolutionize their digital asset trading experience by enabling zero-fee transactions...

at 06:00
Isabelle Hudon, President and CEO of BDC, Canada's bank for entrepreneurs, is pleased to announce the appointment of Maxime Laverdière as BDC's Chief Legal Officer and Corporate Secretary. Maxime will lead the legal and corporate secretariat team,...

at 06:00
Bitget, the leading cryptocurrency exchange and Web3 company, has launched its new fiat Over-the-counter platform for block trade. The service initially supports Euros (EUR), Pounds (GBP) and US Dollar (USD), soon to be extended to Turkish Lira...

at 06:00
While technology has created a convenient and increasingly connected world, where groceries, shopping and global communication are available at our fingertips, a new Leger survey commissioned by AIR MILES reveals two thirds of Canadians feel they...



News published on and distributed by: